Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis

AIMS: This meta-analysis aimed to evaluate the safety and efficacy of regorafenib as a treatment for patients with advanced (metastatic and/or unresectable) gastrointestinal stromal tumor (AGIST) after developing resistance to imatinib and sunitinib. METHODS: A literature search of databases such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhenan, Jiang, Tao, Wang, Wensheng, Piao, Daxun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728743/
https://www.ncbi.nlm.nih.gov/pubmed/29310342
http://dx.doi.org/10.1097/MD.0000000000008698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728743/
https://www.ncbi.nlm.nih.gov/pubmed/29310342
http://dx.doi.org/10.1097/MD.0000000000008698

Ejemplares similares